Science & Technology

232 Items

Report

Tech and Public Policy to Save the Brain

    Authors:
  • Priyamvada Saraf
  • Mathew Alexander
  • Sohaib Nasim
  • Hardy Ding
| May 03, 2023

Neurodegenerative diseases (NDDs) represent a global health emergency, affecting millions of individuals and imposing significant economic burdens. Despite increased funding and government initiatives, effective therapies remain elusive, and NDD research lags behind other fields. This report argues for a simplified, accelerated, and transparent unified approach to NDD research, building on lessons from other fields and industries.

Quantum Computer

Wikimedia Commons

Analysis & Opinions - Foreign Policy

The U.S. Wants to Make Sure China Can’t Catch Up on Quantum Computing

| Mar. 31, 2023

U.S. export controls on China’s semiconductor industry are just the opening salvos in a series of unprecedented export controls on China planned by the Biden administration. After controls on semiconductors, the Commerce Department is moving on to the next emerging technology it worries China could weaponize—quantum computing.

teaser image

Blog Post - perspectives-on-public-purpose

Basic Science Research as the Pillar for NDD Drug Development

| Mar. 24, 2023

In the last decade, there has been a significant increase in the prevalence of neurodegenerative diseases (NDD) in the United States, affecting approximately 10.5 million individuals. This number is predicted to triple in the next 30 years.1 However, in comparison to other disease areas such as oncology, the approval of NDD drugs has been relatively limited. Our team has explored the NDD drug development ecosystem from three perspectives: stakeholders, funding, and policy. This article summarizes our key findings and presents a case study to suggest that the scarcity of new drug development may be attributable to insufficient basic scientific research. Finally, we outline our objectives for the upcoming semester.

Sri Lankan port workers hold a Chinese national flag to welcome Chinese research ship

AP/Eranga Jayawardena, File

Analysis & Opinions - Project Syndicate

Peak China?

| Jan. 03, 2023

Joseph Nye writes: From an American perspective, it is just as dangerous to underestimate Chinese power as it is to overestimate it. While hysteria creates fear, discounting China's recent progress and future ambitions could lead the United States to squander its own long-term advantages.

teaser image

Blog Post - perspectives-on-public-purpose

The Funding Ecosystem for Neurodegenerative Disease

| Dec. 16, 2022

In recent years, there has been an increased focus on finding treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's, as the prevalence of these diseases continues to rise globally. This blog aims to provide an overview of the sources and trends of funding for neurodegenerative disease research, with a particular focus on comparing funding for these diseases with that of other classes of diseases. By examining historical funding trends and the current sources of funding, we seek to shed light on the current state of the funding ecosystem for neurodegenerative disease research. We will also explore how funding is allocated across different types of neurodegenerative diseases and discuss potential bottlenecks in the funding process that may be hindering progress in the development of therapies.

*This blog is part of a series titled TAPP for Neurodegenerative Diseases Drug Discovery: Mapping the ecosystem

teaser image

Blog Post - perspectives-on-public-purpose

The Stakeholders Involved in the Neurodegenerative Disease Drug Development Process

| Dec. 16, 2022

Neurodegenerative diseases (NDDs) are a class of disorders that cause the progressive loss of structure or function of neurons, leading to declines in cognitive and physical abilities. Drug discovery and development for these diseases is a complex, multi-stakeholder process involving a variety of entities across the United States, including government agencies, businesses, research institutions, academic institutions, and non-profit organizations. These stakeholders interact with each other at various stages of the non-linear cycle of drug development, which typically involves a range of activities including pre-clinical research, clinical trials, regulatory approval, and commercialization.

Given the complexity of this process and the challenges involved in developing effective treatments for NDDs, it is important to better understand the role of different stakeholders and the potential barriers they face. This blog aims to provide a deeper examination of the various stakeholders involved in NDD drug discovery and development, and to offer an initial hypothesis on key challenges that may be contributing to the lack of disease-altering therapies for these conditions.

*This blog is part of a series titled TAPP for Neurodegenerative Diseases Drug Discovery: Mapping the ecosystem